Clinical Trials Update: Jan. 18, 2006

Polymyalgia Rheumatica (PMR) Skin Infections/Disorders Sarcoma

(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:

Polymyalgia Rheumatica (PMR)

Medical researchers are currently seeking PMR patients to participate in a clinical research study of a novel treatment given as a subcutaneous injection.

This study includes an open-label extension phase where participating patients receive the active drug.

Qualified participants will receive study-related medication and care at no charge, including physical examinations, evaluations of PMR, laboratory tests and ECG's.

The research site is in Cleveland, Ohio.

More Information

Please see http://www.centerwatch.com/patient/studies/cat733.html.

-----

Skin Infections/Disorders

This is a 12 week study requiring 12 visits to the clinic, using a topical investigational medication to treat solar lentigines (liver or age spots).

Qualified participants should healthy male or female subjects 18-to-65 years old. Females must be postmenopausal or surgically sterilized; forearm of the non-dominant hand must have 2 solar lentigines; participants should have the willingness and ability to comply with scheduled visits, treatment plan, laboratory test and other trial procedures.

The research site is in Madison, Wisc.

More Information

Please see http://www.centerwatch.com/patient/studies/cat177.html.

-----

Sarcoma

Participants in this study should have synovial sarcoma (a soft tissue cancer, usually around the joints) that cannot be removed by surgery or has spread to multiple places in the body.

The purpose of this study is to determine the effects of trastuzumab on response (tumor shrinking or staying the same) and length of life and to evaluate its side effects. Researchers will also be looking at the genetic make-up of the tumor.

The research site is in Duarte, Calif.

More Information

Please see http://www.centerwatch.com/patient/studies/cat134.html.

-----

Copyright 2006 CenterWatch. All rights reserved.

Consumer News